IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
Globe Newswire•16/11/2026•08:00 ET
1
Key Highlights
- ➤INB-200/400 repeat-dose patients reached 20.9-month median overall survival, versus 13.2 months for SOC
- ➤Repeat-dose therapy delivered 13.0-month median progression-free survival, versus 6.6 months for SOC
- ➤Two-year survival reached 50% (7 of 14) with repeat-dose therapy, versus 10% for SOC
- ➤No CRS, ICANS, major infections, treatment-related serious adverse events, or deaths observed
- ➤Repeat-dose patients had lower total surgical resection rates: 43% versus 80% for SOC
Expert Statements
William Ho, CEO and co-founder of IN8bio
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients”
William Ho, CEO and co-founder of IN8bio
“The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence of γδ T cells in patients receiving multiple doses.”
William Ho, CEO and co-founder of IN8bio
“Importantly, across our clinical experience, we have not observed any CRS, ICANS, major infections or treatment-related serious adverse events.”
William Ho, CEO and co-founder of IN8bio
“These data continue to underscore the potential of γδ T cell-based therapies to provide meaningful clinical benefit for patients.”
Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC)
50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group
Get started
Create a free account to read the full story.
